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Clinical Question 
What are the best treatments for impetigo? 
Evidence-Based Answer 
Topical mupirocin (Bactroban) and fusidic acid (not available in the United States) are more 
effective than placebo and at least as effective as oral antibiotics for the treatment of limited 
impetigo, and are better tolerated. (Strength of recommendation [SOR]: A) 
Based on the available evidence on effectiveness, no clear preference can be given for any one 
oral antibiotic over another. (SOR: A) 
Limited evidence does not support the use of topical antiseptics in the treatment of impetigo. 
(SOR: B) 
There is insufficient evidence to compare the effectiveness of topical versus oral antibiotics in 
widespread impetigo. 
Evidence Summary 
Impetigo is the most common skin infection in children two to five years of age, although it can 
occur in patients of any age.1 There has been a shift in the major etiologic agent of this disease 
over the past 40 years from group A beta-hemolytic streptococcus (i.e., Streptococcus pyogenes) 
to Staphylococcus aureus.1,2 Few data are available on the natural course of impetigo. The 
sequelae of streptococcal infections (e.g., glomerulonephritis) do occur, although they are rare. 
There is no evidence that treatment of impetigo prevents these complications.3 
Two recent systematic reviews have cast doubt on the traditional role of oral antibiotics as first-
line therapy for impetigo. The first, a meta-analysis of 57 trials including 3,533 patients, studied 
varying comparisons of 20 oral and 18 topical treatments for impetigo.4 
Topical antibiotics had better cure rates than placebo (odds ratio [OR] = 6.5; 95% confidence 
interval [CI], 3.9 to 10.7), and there was no significant difference between the two most studied 
topical antibiotics, mupirocin and fusidic acid. Ten of these trials compared mupirocin with oral 
erythromycin and showed significantly better cure rates with mupirocin (OR = 1.8; 95% CI, 1.1 
to 3.0). Six of the studies comparing topical to other oral antibiotics (i.e., dicloxacillin 
[Dynapen], cephalexin [Keflex], ampicillin, and penicillin) found no differences among cure 
rates. Twenty-five of the studies, most commonly comparing two oral antibiotics, also showed 
little difference in cure rates between antibiotics. Cephalosporins and macrolide antibiotics, 
usually erythromycin and azithromycin (Zithromax), were most often studied. 
Oral antibiotic therapy caused more side effects than topical therapy. Topical antiseptic agents 
(e.g., hexachlorophene [Phisohex], hydrogen peroxide), which have traditionally been used 
either alone or in conjunction with other therapies, have not been adequately studied or have not 
been compared with placebo treatment. Two older studies were found comparing topical 
antibiotics with antiseptic treatment; pooled data favored topical antibiotic therapy.4 
Another meta-analysis of 16 trials indicated that topical antibiotics are more effective than 
placebo (number needed to treat = 5; OR = 2.7; 95% CI, 1.5 to 4.9).5 There was no significant 
difference found between the two topical antibiotics, mupirocin and fusidic acid. The review 
included three trials comparing oral erythromycin with these topical antibiotics and found weak 
evidence favoring topical therapy (OR = 0.5; 95% CI, 0.2 to 1.0). From the limited high-quality 
evidence available, the authors recommended a seven-day course of topical therapy for healthy 
patients with limited disease. 
Widespread infection can be difficult to treat topically, so oral therapy is often used. A practice 
guideline from the Infectious Diseases Society of America (IDSA)6 recommends oral therapy in 
this situation despite a lack of evidence comparing oral and topical treatment for this subset of 
disease.4-6 The term "widespread" is not clearly defined in most trials.4 Many of the outcomes 
that form the basis for these reviews date back more than 10 years and may not be applicable to 
the current prevalence of infecting agents or resistance patterns against antibiotics. It is unclear 
how the rise of community-acquired methicillin-resistant S. aureus should affect treatment 
choices for impetigo.6 
Recommendations from Others 
The American Academy of Family Physicians and the American Academy of Pediatrics have 
accepted the IDSA guidelines6 but made no unique recommendations themselves. All three 
recommend topical treatment for limited infection and consideration of systemic penicillinase-
resistant antibiotics in more widespread disease.6 
Clinical Commentary 
Impetigo is a common condition seen by most family physicians. Although the evidence shows 
that topical treatment is as good as oral therapy, patient situations still need to be taken into 
consideration. Some patients apply pressure for physicians to prescribe oral antibiotics. Topical 
mupirocin is easy to use but must be applied three times per day and can cost about $70 for a 30-
gm tube. For the uninsured and underinsured, a less expensive course of treatment with an oral 
antibiotic may be preferred; it is all many patients can afford. On occasion, the oral antibiotic 
may be what the patient prefers even if he or she can afford topical treatment. 
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